Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CHINA BIOTECH SERVICES HOLDINGS LIMITED
中國生物科技服務控股有限公司

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)

(Stock code: 8037)

QUARTERLY UPDATE ON IMPLEMENTATION OF ACTION PLAN TO RESOLVE DISCLAIMER OF OPINION

The board (the "**Board**") of directors (the "**Directors**") of China Biotech Services Holdings Limited (the "**Company**", together with its subsidiaries, the "**Group**") would like to provide a quarterly update on the implementation of the action plan (the "**Action Plan**") to resolve the disclaimer of opinion relating to going concern made by the auditors of the Company on the consolidated financial statements of the Group for the year ended 31 December 2024 (the "**Disclaimer of Opinion**"). Unless the context otherwise requires, terms defined in the annual report of the Company for the year ended 31 December 2024 shall have the same meaning when used in this announcement.

(1) Bank borrowings

The management has continued to negotiate with different banks regarding the renewal of banking facilities and obtaining additional funds. A bank borrowing of RMB4,000,000 (equivalent to approximately HK$4,388,000) was renewed in April 2025. A bank borrowing of approximately RMB7,477,000 (equivalent to approximately HK$8,202,000) was also granted by Agricultural Bank of China Limited Qionghai Sub-Branch# (中國農業銀行股份有限公司瓊海市支行) to Pengbo (Hainan).

(2) Other borrowings

The Group has obtained further other borrowings as follows:

- Between May and July 2025, the controlling shareholder of the Company advanced loans in the total principal amount of HK$6,200,000 with a repayment term of 1 year to the Company.

- In June 2025, the Company and Pengbo (Hainan) obtained loans in the principal amount of HK$5,000,000 and RMB2,500,000 (equivalent to approximately HK$2,742,000) respectively from independent third parties which are repayable within 1 year.

(3) Realizing investment in Pillar

The Board has continued with its search for potential purchasers of the Group's investment in Pillar. As at the date of this announcement, no agreement has been entered into for the disposal of this investment.

(4) Operational measures

The Group has been implementing costs control measures including streamlining business processes, reducing staff costs and negotiating price and payment terms with suppliers. The Group will continue to monitor the effectiveness of these operational measures.

(5) Other fundraising activities underway

On 11 July 2025, definitive agreements were entered into in relation to the RMB30,000,000 investment in Dynamic Healthcare Holdings Limited (an indirect wholly-owned subsidiary of the Company) and its subsidiaries (including but not limited to Pengbo (Hainan)) by BGI Songhe Biotechnology No. 1 Private Venture Capital Investment Fund Partnership (Limited Partnership)[#] (深圳市華大松禾生科一號私募創業投資基金合夥企業 (有限合夥)). For details, please refer to the announcement of the Company dated 11 July 2025. As at the date of this announcement, the investment is still in progress.

The Group has also been in talks with various potential investors and financiers (including but not limited to banks, financial institutions and other institutional investors) in relation to equity and debt financing, with the Company, Pengbo (Hainan) and Shanghai Longyao Biotech Company Limited[#] (上海隆耀生物科技有限公司) (an indirect non-wholly owned subsidiary of the Company) being the investment targets. The amount of investments, if materialized, is expected to exceed RMB150 million in aggregate. A number of these financing projects have seen promising progress and are currently undergoing due diligence or internal approval by the investors.

The Board will continue to implement the Action Plan actively with a view to resolving the Disclaimer of Opinion as soon as possible. The Company will publish further announcements on any further updates on the implementation progress as and when appropriate.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

[#] *For identification purposes only*

By order of the Board
China Biotech Services Holdings Limited
Chairman and Executive Director
Liu Xiaolin

Hong Kong, 22 July 2025

As at the date of this announcement, the Board comprises three executive Directors, namely Mr. Liu Xiaolin (Chairman), Mr. He Xun, and Mr. Huang Song; and three independent non-executive Directors, namely Mr. Yan Guoxiang, Dr. Guo Yuantao and Mr. Qian Hongji.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the "Latest Listed Company Information" page of the website of the Stock Exchange at www.hkexnews.hk for at least 7 days from the date of its publication and on the website of the Company at www.cbshhk.com.